Loading
A phase 3 trial of FPI-2265, Cabazitaxel, Abiraterone acetate in prostate cancer, run by AstraZeneca, now recruiting.
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) is a phase 3 interventional study registered as NCT07611110 by AstraZeneca, with 670 participants planned, started 2026-05-04 and due to reach its primary completion in 2029-06-04. Interventions recorded: Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone, Enzalutamide, Apalutamide. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Darolutamide, Apalutamide, Abiraterone acetate, Enzalutamide.
Shares FPI-2265, Metastatic castration-resistant prostate cancer, AstraZeneca, Prostate cancer.
Shares FPI-2265, Metastatic castration-resistant prostate cancer, AstraZeneca, Prostate cancer.
Shares Apalutamide, Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Cabazitaxel, Abiraterone acetate, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Darolutamide, Apalutamide, Abiraterone acetate, Enzalutamide.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/